Tatva Chintan Pharma Chem Ltd Q2 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/o1y8zcwb33ludu97haos6t19.pdf

Key Takeaways


Revenue & the Goods-in-Transit Distortion

Chintan Shah: "So, I think this is the end of what worst we can see is what we are spending at as of now. And now we are absolutely optimistic of gaining from here."

SDA: The Core Business Under Pressure

Chintan Shah: "So, my strong belief is there is no going down further from here. The only way it can go is move up. So, they are really at unrealistically low levels as of today. Meeting probably records of last 20 years."

New Product Pipeline: The FY26 Growth Engine

Chintan Shah: "I'm trying to be very conservative in the way we have been talking and things have been evolving in the last few quarters. I'm trying to be very conservative in what I'm saying."

Margins & Costs


Competitive Landscape & Market Context

Chintan Shah: "Logically, I think that could be a matter of concern for the customer, whether it is really not impacting the market, that may be true. But probably that has impacted the psychology, the way the customer thinks."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue troughQ3 revenue "more or less similar to current numbers or maybe a little better"; this is "the end of what worst we can see"Q3 FY25
Full-year revenueDownward revision from prior expectations; H2 to "potentially reflect or slightly better" than H1FY25
Revenue recoveryGradual uptick in demand; new products to fill the growth gap and deliver "decent growth"From Q4 FY25; FY26
Flame retardants shipmentFirst commercial-scale plant approval trial order to shipQ3 FY25
Electrolyte customer discussionsCommercial discussions to concludeDiwali / mid-November 2024
Monoglyme commercializationProduction installation and commercialization to beginEnd of calendar year 2025
SDA recoveryEuro-7 commercialization to show "real strong foothold"; commercial vehicle sales recovery anticipatedMid-to-end 2025
Electrolyte salts demandSignificant growth from energy storage customerEarly 2025
Electrolyte salts second customerOnset of commercialization for hybrid vehicle applicationSecond half of 2025
PASC pharma intermediateGradual demand uptick2025
PASC pharma intermediateFull-scale demand2026
Large-volume PTC opportunityCommercializationCalendar year 2026
New distillation plantGround-breaking post-Diwali; operational after 1 yearNovember 2025
Capacity ceilingExpect to run out of capacity even after new capexWithin 1-1.5 years

Key Metrics

MetricQ2 FY25
Revenue from operations₹83.5 cr, 14% decline YoY and 21% decline QoQ
EBITDA₹5.6 cr, 37% drop YoY and 23% decline QoQ
EBITDA margin6.7%, decreased by 14% YoY due to increase in COGS and other expenses by 12.6% and 1.6% respectively
PAT marginnegative 0.8% vs 8% in Q2 FY24
Exports₹50.8 cr, contributing 60% of revenue
Phase Transfer Catalyst revenue₹27.5 cr, 8% decline QoQ, 19% growth YoY
Structure Directing Agents revenue₹27.1 cr, 23% decline QoQ and 37% drop YoY
Pharma & Agro Intermediates and Specialty Chemicals revenue₹27.2 cr, 30% decline QoQ and 5% decline YoY
Electrolyte Salts revenue₹3 cr, 5% decline QoQ, 8% growth YoY
Cost of materials consumed50–51% of revenue, down from ~54% in prior quarters
Goods in transit₹17.53 cr, up from ₹7.1 cr in Q1 FY25; additional ₹10.5 cr of executed orders not yet invoiced
New distillation plant capex₹104–105 cr, ground-breaking post-Diwali, operational by November 2025
SDA market share~15–16% globally; market size nearly 7x current volumes, expected to grow ~50% with Euro 7 norms
Phase Transfer Catalyst export market share~25–30% of volumes
New product revenue pipeline (3 pharma + 3 agro)₹80–100 cr estimated for FY26, potentially doubling to ₹200–250 cr in FY27